TD Waterhouse Canada Inc. Increases Holdings in Eli Lilly and Company $LLY

TD Waterhouse Canada Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 88,315 shares of the company’s stock after purchasing an additional 3,578 shares during the period. TD Waterhouse Canada Inc.’s holdings in Eli Lilly and Company were worth $72,979,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Lazard Freres Gestion S.A.S. raised its holdings in Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after purchasing an additional 41,222 shares in the last quarter. Exencial Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 189.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after buying an additional 11,396 shares in the last quarter. Rede Wealth LLC bought a new position in Eli Lilly and Company during the third quarter valued at approximately $487,000. Precedent Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after acquiring an additional 39 shares during the period. Finally, Central Pacific Bank Trust Division grew its position in Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after buying an additional 1,843 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,024.14 on Thursday. The company has a market capitalization of $968.20 billion, a P/E ratio of 50.10, a P/E/G ratio of 0.79 and a beta of 0.35. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock’s fifty day moving average is $1,057.65 and its two-hundred day moving average is $886.06. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm earned $1.18 earnings per share. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Signed a potential $1.93 billion deal with Repertoire to develop autoimmune therapies — expands Lilly’s immune?disease pipeline and adds milestone/licensing upside that could underpin future revenue growth and valuation. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: Entered a deal (up to ~$1.12B) with Seamless Therapeutics to develop gene?editing treatments for hearing loss — adds high?value, high?optionality programs and gives Lilly exposure to novel recombinase technology. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: Oncology and AI catalysts: coverage highlights Lilly’s oncology pipeline plus a ~$1B AI collaboration with Nvidia to speed drug discovery — could accelerate new launches and support mid?term revenue growth. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Positive Sentiment: Analyst/earnings setup looks favorable: earnings?surprise history and consensus expectations point to another likely beat, supporting near?term sentiment around fundamentals. Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Positive investor writeups and “top picks” pieces argue for multi?year growth driven by GLP?1 leadership and pipeline, but these are opinion pieces that may already be priced in. Top Picks 2026: Eli Lilly & Co.
• Negative Sentiment: Medicare drug price negotiation named a Lilly Part B product (Verzenio) for talks — introduces downside risk to pricing and margins if negotiated cuts apply to key products. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Competitive pressure: Reuters data shows Novo Nordisk doubled U.S. ad spend vs. Lilly for GLP?1s — implies intensified market share battle and potentially higher marketing costs or share erosion. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Market reaction note: coverage points out shares fell even after the gene?editing tie?ups, signaling investor concerns about valuation, near?term growth execution, or policy/competitive risks despite the deals. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership

Analyst Upgrades and Downgrades

A number of research firms have commented on LLY. Guggenheim decreased their target price on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Leerink Partners set a $1,234.00 price objective on shares of Eli Lilly and Company in a research report on Monday, January 5th. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. HSBC restated a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $1,173.91.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.